ARASENS: Will combining different treatments improve prostate cancer survival?

Advanced Prostate Cancer Clinical Trials Update 2022Подробнее

Fighting Aggressive Prostate Cancer with Combination Therapy | Living MinuteПодробнее

Combination therapy for patients with prostate cancerПодробнее

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPCПодробнее

ESMO Expert Report on combination therapy in advanced prostate cancer @ ASCO GU 2022Подробнее

2022 ASCO Genitourinary Cancers Symposium Research Updates Webinar with Dr. Alexandra SokolovaПодробнее

ARASENS: the addition of darolutamide to ADT and docetaxel for the treatment of mHSPCПодробнее

Combination Therapy & Hormone Therapy | Ask a Prostate Expert, Mark Scholz, MDПодробнее

ARASENS: dialuramide plus ADT and docetaxel for metastatic hormone-sensitive prostate cancerПодробнее

Combination therapies for the treatment of prostate cancerПодробнее

Prostate cancer update: practice-changing data?Подробнее

Recent developments in treatment options for castration-sensitive metastatic prostate cancerПодробнее

Combination Therapy in Hormone-Sensitive Prostate CancerПодробнее

Immune, Hormone, & Radiation Combined for Prostate Cancer | Ask a Prostate Expert, Mark Scholz, MDПодробнее

Early Treatment Intensification for mCSPC: Optimising Patient Selection and TreatmentПодробнее

GU ASCO Symposium 2022 SummaryПодробнее

A New Standard of Care - improving prostate cancer cure rates in high-risk patientsПодробнее

Combining SBRT and Brachytherapy in Higher Risk Prostate CancerПодробнее

Prostate cancer and future hopes for treatmentПодробнее

AUA: Sequencing Of Agents And Combination Therapy In Castrate Resistant Prostate CancerПодробнее